The [18F]-labelled insulin, studied by Smith et al., demonstrated rapid and efficient brain delivery via a catheter-based liquid method, making it highly effective for targeting limbic and frontotemporal regions critical for Alzheimer's disease treatment 2. This evidence concerns the gene INS and early-onset autosomal dominant Alzheimer disease.